This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
|Zacks Rank||Definition||Annualized Return|
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at email@example.com or call 800-767-3771 ext. 9339.
For Immediate Release
Chicago, IL – August 27, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Tiffany & Company (NYSE:(TIF - Analyst Report), Signet Jewelers Limited (NYSE:(SIG - Snapshot Report), Zale Corporation (NYSE:(ZLC - Snapshot Report), Walgreen (NYSE:(WAG - Analyst Report) and Greenway Medical Technologies, Inc. (NYSE:(GWAY - Snapshot Report).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Friday’s Analyst Blog:
Earnings Preview: Tiffany
Tiffany & Company (NYSE:(TIF - Analyst Report) is slated to report its second-quarter 2012 financial results on August 27, 2012. The current Zacks Consensus Estimate for the quarter stands at 75 cents a share, indicating an estimated year-over-year decrease of about 12.8%. Revenue, as per the Zacks Consensus Estimate, is $887 million.
Tiffany’s quarterly earnings of 64 cents a share, missed the Zacks Consensus Estimate of 69 cents, and dropped from 67 cents earned in the prior-year quarter. Tiffany, which faces stiff competition from Signet Jewelers Limited (NYSE:(SIG - Snapshot Report) and Zale Corporation (NYSE:(ZLC - Snapshot Report), posted net sales of $819.2 million during the quarter, up 8% from the prior-year quarter. Total revenue came ahead of the Zacks Consensus Estimate of $818 million.
Guidance Went Down
Given the weaker-than-expected results and sluggish economic recovery in most of the countries, management trimmed its fiscal 2012 outlook. The company projects earnings in the range of $3.70 to $3.80 per share, down from $3.95 to $4.05 forecasted earlier. Moreover, total net sales are expected to grow in the range of 7% to 8%, down from 10% predicted previously.
Agreement of Estimate Revisions
During the last 30 days, 4 out of 18 estimates have been revised downwards, while none were increased for the upcoming quarter. Moreover, for fiscal 2012 the story remains the same with 5 estimates (out of 19) being revised downwards, while none were revised higher.
In the last seven days, 2 out of 19 estimates have been revised downwards for fiscal 2012, while none were raised.
Magnitude of Estimate Revisions
The Zacks Consensus Estimate for the quarter remained stable over the last 30 days. For fiscal 2012, estimates decreased 4 cents to $3.63, as analysts expect both revenue and earnings to decline in comparison to the prior year, on account of a sluggish economic recovery in most of the countries and soft demand for jewelry. Moreover, the downward pressure on earnings estimates was also in response to the guidance cut.
Mixed Surprise History
With respect to earnings surprises, Tiffany has beat as well as missed the Zacks Consensus Estimate over the last four quarters in the range of negative 7.3% to positive 22.9%. The average remained at positive 7.5%, indicating that the company has surpassed the Zacks Consensus Estimate by the same magnitude in the trailing four quarters.
Currently, the stock holds a Zacks #3 Rank that translates into a short-term ‘Hold’ rating. However, we maintain a long-term ‘Underperform’
rating on Tiffany following the lackluster outlook provided for the current fiscal.
New EHR for Walgreen
In an effort to provide greater flexibility to health care customers, Walgreen (NYSE:(WAG - Analyst Report) recently started installing WellHealth EHR, the electronic health record (EHR) solution from Greenway Medical Technologies, Inc. (NYSE:(GWAY - Snapshot Report), a player in the health care information technology (HCIT) market. The drug retail giant has already deployed the EHR in over 200 of its stores and plans to introduce it across 8,000 locations by the summer of next year.
As a part of Walgreen’s HealthCloud initiative, the EHR solution will help the company transform its traditional drugstores to health and daily living destinations. Working as a single patient view of Walgreen, the WellHealth EHR will provide the latest patient immunization and health testing information, along with pharmacy information irrespective of where the patient received the service. The two parties entered into a partnership in 2010 when Walgreen first deployed Greenway’s PrimeSuite in Walgreen’s worksite health centers for primary and acute care.
With the recent verdict of the Supreme Court upholding the Patient Protection and Affordable Care Act of 2010 (PPACA) (also known as Obamacare), the U.S. health care industry is making an all-out effort to rope in hospitals, doctors, pharmacists and others through the EHR and electronic medical records (EMRs).
The recent data shows that the number of hospitals using health information technology (IT) has more than doubled in the last two years.
Moreover, nearly 2,000 hospitals and more than 41,000 doctors have received $3.1 billion in incentive payments for ensuring ‘Meaningful Use’
of health IT, particularly, certified EHR. The incentives will be offered for a period of 4–5 years, after which physicians will be penalized for not adopting proper measures.
Notably, “Meaningful Use” is a criterion specified under the EHR incentive program, which is designed to stimulate the use of technology in healthcare. Funded by the HITECH Act, the program enables providers to adopt EHR and meet Meaningful Use needs in order to earn reimbursements and avoid Medicare penalties.
We believe that Walgreen is well placed to gain a meaningful share of the multi-billion dollar American Recovery and Reinvestment Act (ARRA)-related healthcare information technology investment opportunity. We have a long-term Neutral recommendation on Walgreen. The stock currently retains a Zacks #3 Rank, which translates into a short-term Hold rating.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339
Please login to Zacks.com or register to post a comment.